NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones With Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones With Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
New Nasdaq Ticker Symbol will be MTVA
納斯達克的新逐筆明細標的將是MTVA
CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date"). In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, and a new company logo, on the Effective Date.
馬薩諸塞州劍橋,2024年11月18日/PRNewswire/ - NeuroBo Pharmaceuticals, Inc. (納斯達克: NRBO),一家臨床階段生物技術公司,專注於改善心臟代謝性疾病,今天宣佈在重要臨床里程碑之前進行戰略重新調整,公司更名爲"MetaVia Inc.",將於2024年11月29日("生效日")生效。 與此同時,公司的普通股將在納斯達克股市以新的逐筆明細代碼"MTVA"開始交易,預計將於生效日起生效。作爲公司更名的一部分,公司還將在生效日推出新網站metaviatx.com和新公司標識。
The Company's CUSIP number and transfer agent will remain unchanged. Shareholders were not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company's operations, management or structure.
公司的CUSIP編號和過戶代理將保持不變。股東不需要採取任何具體行動來應對公司更名或新的逐筆明細標的。公司的更名和新的逐筆明細標的不會影響公司的運營、管理或結構。
"Our corporate name change to MetaVia, ahead of important clinical milestones, represents the final step in our transition to develop innovative therapies for the management of cardiometabolic diseases, since in-licensing our two next generation assets from our strategic partner, Dong-A ST Co., Ltd., targeting the obesity and metabolic dysfunction-associated steatohepatitis (MASH) markets," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "We remain well-funded following our successful June financing of up to $70 million in aggregate gross proceeds, with $20 million upfront and $50 million of clinical milestone-based warrants.
神經波首席執行官金亨賢表示:"在重要臨床里程碑之前,我們將公司更名爲MetaVia,這代表着我們轉型發展創新治療心臟代謝性疾病的最後一步,自從從戰略伙伴東亞聖公司處許可我們的兩個下一代資產,主要針對肥胖和代謝紊亂相關的脂質肝炎(MASH)市場。" "在成功進行了截至總額爲7000萬美元的六月融資後,我們的資金狀況良好,其中包括2000萬美元的預付款和基於臨床里程碑的5000萬美元的認股權證。
"As previously announced, in December 2024, we expect to report data from the Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of MASH. Additionally, in the first quarter of next year, we anticipate reporting top-line data from the planned cohorts from the multiple ascending dose (MAD) portion of our Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Based on the preclinical data generated to date, as well as DA-1726's balanced activation of GLP1R and glucagon receptors, which increases energy expenditure, we believe that DA-1726 may become a best-in-class obesity drug with a better tolerability profile than currently marketed GLP-1 agonists, and those now in late-stage clinical trials."
如先前宣佈的,我們預期在2024年12月報告DA-1241的2a期臨床試驗數據,評估這種新型G蛋白耦聯受體119(GPR119)激動劑用於治療MASH的療效和安全性。此外,明年第一季度,我們計劃報道DA-1726的計劃分級升劑量(MAD)部分的頂線數據,這是一種新型的雙氧肽素(OXM)類似物激動劑,具有糖皮質激素樣肽-1受體(GLP1R)和糖皮肽受體(GCGR)的功能,用於治療肥胖。 根據迄今產生的臨床前數據,以及DA-1726平衡激活GLP1R和糖皮肽受體,增加了能量消耗,我們相信DA-1726有可能成爲一種擁有更好耐受性概況的最佳肥胖藥物,優於目前市場上的GLP-1激動劑和目前處於後期臨床試驗階段的藥物。
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
關於NeuroBo Pharmaceuticals
neurobo pharmaceuticals股份有限公司是一家專注於轉化心臟代謝疾病的臨床生物技術公司。該公司目前正在開發DA-1726用於肥胖治療,正在開發DA-1241用於治療代謝功能相關脂肪肝(MASH)。DA-1726是一種新型氧雲調質激素(OXM)類似物,作爲胰高血糖素樣肽-1受體(GLP1R)和胰高血糖素受體(GCGR)雙激動劑發揮作用。OXm是一種天然存在的腸道激素,能激活GLP1R和GCGR,從而減少食物攝入量並增加能量消耗,從而可能導致相對於選擇性GLP1R激動劑更好的體重減輕。DA-1241是一種新型的G蛋白偶聯受體119(GPR119)激動劑,能促進關鍵的腸道肽GLP-1,GIP和PYY的釋放。在臨床前研究中,DA-1241顯示出對肝臟炎症,脂質代謝,體重減輕和葡萄糖代謝具有積極作用,減少肝脂變性,肝炎炎症和肝纖維化,同時改善葡萄糖控制。
For more information, please visit .
更多資訊,請訪問。
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with NeuroBo's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of NeuroBo's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of NeuroBo's contract manufacturers, clinical study partners and others involved in the development of NeuroBo's current and future product candidates; potential negative interactions between NeuroBo's product candidates and any other products with which they are combined for treatment; NeuroBo's ability to initiate and complete clinical trials on a timely basis; NeuroBo's ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to NeuroBo's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in NeuroBo's filings with the Securities and Exchange Commission, including NeuroBo's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
前瞻性聲明
本新聞稿中的某些聲明可能被視爲根據1995年《私人證券訴訟改革法案》的意義屬前瞻性聲明。諸如"相信"、"預計"、"期待"、"可能"、"將"、"應該"、"尋求"、"大約"、"潛在"、"意圖"、"項目"、"計劃"、"估計"等詞或這些詞的否定形式,或其他類似術語(以及其他涉及未來事件、狀況或情況的詞語或表達)旨在識別前瞻性聲明。前瞻性聲明預測、投影及其他關於基於當前期望和假設的未來事件的聲明,並因此受到風險和不確定性的影響。許多因素可能導致實際未來事件與本新聞稿中前瞻性聲明大不相同,包括但不限於與NeuroBo執行其商業策略的風險相關的那些風險;監管提交的時間表;通過NeuroBo當前和未來產品候選品的開發步驟獲得監管批准的能力;實現與東亞製藥的許可協議對NeuroBo未來的金融和運營結果的影響,包括NeuroBo與其代工廠商、臨床研究合作伙伴和其他參與NeuroBo當前和未來產品候選品開發的人之間的合作;NeuroBo產品候選品與聯合治療的任何其他產品之間潛在負面交互的能力;NeuroBo及時啓動和完成臨床試驗的能力;NeuroBo招募臨床試驗對象的能力;NeuroBo是否從臨床試驗中獲得與前臨床和先前臨床試驗結果一致的結果;與許可協議相關的已知和未知成本的影響,包括與許可協議有關的任何訴訟或監管行動的成本;適用法律或法規變化的影響;NeuroBo股價變化對許可協議條款和任何未來融資的影響;以及NeuroBo在提交給證券交易委員會的申報中描述的其他風險和不確定性,包括NeuroBo最近的年度報告10-k的。前瞻性聲明僅在作出時有效。NeuroBo並不承擔任何公開更新或修訂前瞻性聲明的義務,除非法律要求。
Contacts:
聯繫人:
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]
NeuroBo Pharmaceuticals
Marshall H. Woodworth
首席財務官
+1-857-299-1033
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
SOURCE NeuroBo Pharmaceuticals, Inc.
來源:NeuroBo Pharmaceuticals,Inc。